Evidence map›Paper›PMID 31098882›Full record

SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2019

EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review.

Valentina Prevolnik Rupel, Marko Divjak, Zsombor Zrubka, Fanni Rencz, László Gulácsi, Dominik Golicki, Dagmara Mirowska-Guzel, Judit Simon, Valentin Brodszky, Petra Baji and 4 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Deciphering Multiple Sclerosis Progression.Frontiers in neurology · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Valentina Prevolnik RupelInstitute for Economic Research, Kardeljeva ploščad 17, 1000, Ljubljana, Slovenia. rupelv@ier.si.ORCID http://orcid.org/0000-0002-1238-7156
Marko DivjakDOBA Business School, Prešernova ulica 1, 2000, Maribor, Slovenia.ORCID http://orcid.org/0000-0001-9595-0954
Zsombor ZrubkaDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0002-1992-6087
Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0001-9674-620X
László GulácsiDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0002-9285-8746
Dominik GolickiDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0001-7741-4760
Dagmara Mirowska-GuzelDepartment of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology, Medical University of Warsaw, Poland, ul. Banacha 1b, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0001-6294-3256
Judit SimonDepartment of Health Economics, Centre for Public Health, Medical University of Vienna, Kinderspitalgasse 15/1, Vienna, 1090, Austria.ORCID http://orcid.org/0000-0001-9279-8627
Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0002-6095-2295
Petra BajiDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0003-2899-8557
Jakub ZávadaInstitute of Rheumatology, Na Slupi 4, 128 00, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-9802-6545
Guenka PetrovaDepartment of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University, Sofia, Bulgaria.ORCID http://orcid.org/0000-0001-8116-5138
Alexandru RotarDepartment of Social Medicine, University of Amsterdam, Meibergdreef 9, 22660, 1100 DD, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1382-7093
Márta PéntekDepartment of Health Economics, Corvinus University of Budapest, Fővám tér 8., H-1093, Budapest, Hungary.ORCID http://orcid.org/0000-0001-9636-6012

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backroundGuidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases.

methodsA systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed.

resultsThirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest.

conclusionsEQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.

Indexed as

Activities of Daily LivingEuropeEurope, EasternHumansMental HealthNervous System DiseasesPainPhysical Functional PerformanceQuality of LifeSelf CareSeverity of Illness IndexCentral and Eastern European countriesEQ-5DHealth-related quality of lifeNeurological diseases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.